Mark Peterson

After a turbulent year, Cycurion's $6M private placement signals a major comeback, funding an aggressive push into AI cybersecurity and acquisitions.

Enveric Biosciences heads to J.P. Morgan Week to pitch its novel non-hallucinogenic neuroplastogens. Can it secure the deals to disrupt mental health?

Reeling from a trial failure, Neuphoria Therapeutics battles an activist's lowball bid while its board scrambles to unlock hidden value in a high-stakes review.

A novel drug aims to replace toxic chemo and conquer aggressive breast cancer. Can Intensity Therapeutics' direct tumor injection shift the treatment paradigm?

An Israeli biotech's manufacturing milestone isn't just a production win; it's a strategic move to commercialize its nasal shield technology.

A $3M deal values Eye-Net's V2X tech at $55M, but the complex warrant structure tells a deeper story about Foresight's strategic play in road safety.

Fresh off a massive IPO, MapLight Therapeutics is racing toward pivotal data in schizophrenia and Alzheimer's. Can it defy the odds in biotech's riskiest field?

With nickel prices low, FPX Nickel is doubling down on its own stock. Is this a savvy capital move or a signal of a unique, undervalued asset?

uniQure’s promising gene therapy for Huntington's disease hits a major FDA roadblock, sending its stock tumbling and delaying hope for patients.

How a craft soda maker and a gaming giant turned a niche beverage into a national sensation, rewriting the rules of fan engagement and retail strategy.

A $1.8M military deal for its unique aluminum foam positions Cymat to capitalize on rising defense spending. But can it turn tech wins into profit?

The European Commission dismissed NGO objections to a key copper project, signaling a new era for Europe's resource security and its green transition.

With a micro-financing, new board, and a 15-for-1 share consolidation, is junior explorer Infinico Metals executing a savvy turnaround or just surviving?

The Danish biotech just locked in billions in financing for its Merus N.V. buyout. It's a high-stakes bet on a new cancer drug to redefine its future.

A biotech firm's novel 'CD45 engager' could make off-the-shelf cell therapies a reality, starting with a tough-to-treat blood cancer. Is this a market disruptor?

A 30% dealer sales jump shows demand for American-made safes. But can this success secure the future of its financially struggling parent company, AREB?

RNAi leader Alnylam swaps scientific oversight for commercial firepower in a key board reshuffle, signaling a strategic pivot to dominate the market.

After a $1B trial in Brazil, Rezolve AI is bringing its AI-powered stablecoin payment system to the West. Can it navigate the regulatory maze?

Beyond the numbers, CACI's renewed $145M pact with the U.S. Navy is a critical investment in America's submarine readiness. Here's the strategic analysis.

Stem's move to add CEO Arun Narayanan to its board is more than a title change; it's a strategic gambit to accelerate its software-first future.